JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathiesGina A. Montealegre Sanchez, Jonathan Janes, Adam Reinhardt et al.|Journal of Clinical Investigation|2018Cited by 519
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trialsEric L. Simpson, Kristian Reich, Jonathan I. Silverberg et al.|British Journal of Dermatology|2020Cited by 377
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*Jean‐Louis Vincent, Jonathan Janes, Gordon R. Bernard et al.|Critical Care Medicine|2005Cited by 321
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)Andrew F. Shorr, for the RESPOND Investigators, Antonio Artigas et al.|Critical Care|2010Cited by 16